• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过用加州电鳐乙酰胆碱受体免疫大鼠对实验性自身免疫性重症肌无力(EAMG)模型进行标准化——方法和实验设计建议

Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

作者信息

Losen Mario, Martinez-Martinez Pilar, Molenaar Peter C, Lazaridis Konstantinos, Tzartos Socrates, Brenner Talma, Duan Rui-Sheng, Luo Jie, Lindstrom Jon, Kusner Linda

机构信息

Division Neuroscience, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.

Division Neuroscience, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.

出版信息

Exp Neurol. 2015 Aug;270:18-28. doi: 10.1016/j.expneurol.2015.03.010. Epub 2015 Mar 18.

DOI:10.1016/j.expneurol.2015.03.010
PMID:25796590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4466156/
Abstract

Myasthenia gravis (MG) with antibodies against the acetylcholine receptor (AChR) is characterized by a chronic, fatigable weakness of voluntary muscles. The production of autoantibodies involves the dysregulation of T cells which provide the environment for the development of autoreactive B cells. The symptoms are caused by destruction of the postsynaptic membrane and degradation of the AChR by IgG autoantibodies, predominantly of the G1 and G3 subclasses. Active immunization of animals with AChR from mammalian muscles, AChR from Torpedo or Electrophorus electric organs, and recombinant or synthetic AChR fragments generates a chronic model of MG, termed experimental autoimmune myasthenia gravis (EAMG). This model covers cellular mechanisms involved in the immune response against the AChR, e.g. antigen presentation, T cell-help and regulation, B cell selection and differentiation into plasma cells. Our aim is to define standard operation procedures and recommendations for the rat EAMG model using purified AChR from the Torpedo californica electric organ, in order to facilitate more rapid translation of preclinical proof of concept or efficacy studies into clinical trials and, ultimately, clinical practice.

摘要

抗乙酰胆碱受体(AChR)的重症肌无力(MG)的特征是随意肌出现慢性、易疲劳性无力。自身抗体的产生涉及T细胞的失调,T细胞为自身反应性B细胞的发育提供环境。症状是由IgG自身抗体(主要是G1和G3亚类)破坏突触后膜和降解AChR所致。用来自哺乳动物肌肉的AChR、来自电鳐或电鳗电器官的AChR以及重组或合成的AChR片段对动物进行主动免疫可产生MG的慢性模型,称为实验性自身免疫性重症肌无力(EAMG)。该模型涵盖了参与针对AChR免疫反应的细胞机制,例如抗原呈递、T细胞辅助和调节、B细胞选择以及分化为浆细胞。我们的目标是定义使用来自加州电鳐电器官的纯化AChR建立大鼠EAMG模型的标准操作程序和建议,以便促进将临床前概念验证或疗效研究更快地转化为临床试验,并最终转化为临床实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23bf/4466156/44cca5be949a/nihms678807f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23bf/4466156/ba6cf573a32c/nihms678807f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23bf/4466156/44cca5be949a/nihms678807f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23bf/4466156/ba6cf573a32c/nihms678807f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23bf/4466156/44cca5be949a/nihms678807f2.jpg

相似文献

1
Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.通过用加州电鳐乙酰胆碱受体免疫大鼠对实验性自身免疫性重症肌无力(EAMG)模型进行标准化——方法和实验设计建议
Exp Neurol. 2015 Aug;270:18-28. doi: 10.1016/j.expneurol.2015.03.010. Epub 2015 Mar 18.
2
Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.用重组表达的LRP4进行免疫可诱导C57BL/6小鼠发生实验性自身免疫性重症肌无力。
Immunol Invest. 2017 Jul;46(5):490-499. doi: 10.1080/08820139.2017.1299754. Epub 2017 Apr 4.
3
Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization.乙酰胆碱受体免疫诱导重症肌无力小鼠模型的标准临床前实验指南。
Exp Neurol. 2015 Aug;270:11-7. doi: 10.1016/j.expneurol.2015.02.009. Epub 2015 Feb 16.
4
Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.IL-10修饰的树突状细胞对Lewis大鼠实验性自身免疫性重症肌无力的保护作用
Neurobiol Dis. 2004 Jul;16(2):461-7. doi: 10.1016/j.nbd.2004.03.017.
5
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.实验性自身免疫性重症肌无力的病理机制。II. 用抗乙酰胆碱受体抗体在大鼠中被动转移实验性自身免疫性重症肌无力
J Exp Med. 1976 Sep 1;144(3):739-53. doi: 10.1084/jem.144.3.739.
6
Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice.经加利福尼亚扁尾海蛇乙酰胆碱受体(Torpedo californica AChR)与灭活百日咳博德特氏菌和完全弗氏佐剂混合注射,可增加 C57BL/6 小鼠实验性自身免疫性重症肌无力的发生。
Autoimmunity. 2017 Aug;50(5):293-305. doi: 10.1080/08916934.2017.1329831. Epub 2017 May 26.
7
Animal models of myasthenia gravis.重症肌无力的动物模型
Clin Immunol. 2000 Feb;94(2):75-87. doi: 10.1006/clim.1999.4807.
8
Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.实验性自身免疫性重症肌无力中乙酰胆碱受体抗体的光谱分型分析。
Clin Exp Immunol. 1984 Jul;57(1):41-50.
9
Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.通过用乙酰胆碱受体的互补肽操纵免疫网络预防实验性自身免疫性重症肌无力
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8747-51. doi: 10.1073/pnas.90.18.8747.
10
Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.实验性自身免疫性重症肌无力的病理机制。I. 同基因肌肉乙酰胆碱受体的免疫原性以及从实验性自身免疫性重症肌无力大鼠肌肉中定量提取受体和抗体 - 受体复合物
J Exp Med. 1976 Sep 1;144(3):726-38. doi: 10.1084/jem.144.3.726.

引用本文的文献

1
Hock immunization, a refined alternative for developing experimental autoimmune myasthenia gravis (EAMG) in mice.霍克免疫法,一种用于在小鼠中诱发实验性自身免疫性重症肌无力(EAMG)的改良方法。
Sci Rep. 2025 Aug 29;15(1):31893. doi: 10.1038/s41598-025-12446-0.
2
Differential Scanning Calorimetry as a Monitoring Tool for the Effectiveness of Therapeutic Plasma Exchange in Anti-AChR Myasthenia Gravis, Anti-MuSK Myasthenia Gravis, and Myasthenic Syndrome: A Case Series.差示扫描量热法作为监测抗乙酰胆碱受体重症肌无力、抗肌肉特异性激酶重症肌无力和肌无力综合征治疗性血浆置换疗效的工具:病例系列
J Clin Med. 2025 Jul 14;14(14):4968. doi: 10.3390/jcm14144968.
3

本文引用的文献

1
Rigor or mortis: best practices for preclinical research in neuroscience.僵直或尸僵:神经科学临床前研究的最佳实践。
Neuron. 2014 Nov 5;84(3):572-81. doi: 10.1016/j.neuron.2014.10.042.
2
Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis.用于实验性自身免疫性重症肌无力的抗原特异性免疫治疗疫苗。
J Immunol. 2014 Nov 15;193(10):5044-55. doi: 10.4049/jimmunol.1401392. Epub 2014 Oct 6.
3
Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.
Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.
泊维他西普(ALPN - 303;TACI vTD - Fc),一种增强的、强效的BAFF和APRIL双重抑制剂,可改善C57BL/6N小鼠的实验性自身免疫性重症肌无力。
Front Immunol. 2025 Jun 6;16:1533093. doi: 10.3389/fimmu.2025.1533093. eCollection 2025.
4
Hypothalamic kisspeptin alleviates myasthenia gravis by regulating Th1/Th17/Treg balance through Inhibition of NF-κB signaling pathway.下丘脑 kisspeptin 通过抑制 NF-κB 信号通路调节 Th1/Th17/Treg 平衡来缓解重症肌无力。
J Neuroinflammation. 2025 Jun 16;22(1):158. doi: 10.1186/s12974-025-03486-4.
5
Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients.MLN9708(伊沙佐米)在实验性自身免疫性重症肌无力及重症肌无力患者产生抗乙酰胆碱受体的原发性胸腺细胞培养物中的疗效。
Front Immunol. 2025 May 15;16:1521432. doi: 10.3389/fimmu.2025.1521432. eCollection 2025.
6
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis.补体在重症肌无力发病机制及治疗中的作用
Cells. 2025 May 19;14(10):739. doi: 10.3390/cells14100739.
7
Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.重组乙酰胆碱受体免疫诱导小鼠实验性自身免疫性重症肌无力的稳健模型。
Cells. 2024 Mar 14;13(6):508. doi: 10.3390/cells13060508.
8
MicroRNA‑155‑5p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis.微小RNA-155-5p通过靶向重症肌无力中的BCL10影响调节性T细胞活化和免疫抑制功能。
Exp Ther Med. 2023 Nov 9;27(1):6. doi: 10.3892/etm.2023.12293. eCollection 2024 Jan.
9
Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.重症肌无力的治疗:从旧药物到创新疗法,展望未来。
CNS Drugs. 2024 Jan;38(1):15-32. doi: 10.1007/s40263-023-01059-8. Epub 2024 Jan 11.
10
Impaired cerebral microvascular endothelial cells integrity due to elevated dopamine in myasthenic model.由于肌无力模型中多巴胺升高导致脑微血管内皮细胞完整性受损。
J Neuroinflammation. 2024 Jan 4;21(1):10. doi: 10.1186/s12974-023-03005-3.
生存素作为支持重症肌无力自身反应性细胞存活的潜在介质:一项人类和动物模型研究
PLoS One. 2014 Jul 22;9(7):e102231. doi: 10.1371/journal.pone.0102231. eCollection 2014.
4
Expression of a highly antigenic and native-like folded extracellular domain of the human α1 subunit of muscle nicotinic acetylcholine receptor, suitable for use in antigen specific therapies for Myasthenia Gravis.人肌肉型烟碱型乙酰胆碱受体α1亚基高抗原性且具有天然样折叠的细胞外结构域的表达,适用于重症肌无力的抗原特异性治疗。
PLoS One. 2013 Dec 20;8(12):e84791. doi: 10.1371/journal.pone.0084791. eCollection 2013.
5
Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?针对浆细胞的蛋白酶体抑制剂:在治疗重症肌无力中的可能作用?
Ann N Y Acad Sci. 2012 Dec;1274:48-59. doi: 10.1111/j.1749-6632.2012.06824.x.
6
Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.主要免疫原性区域和内源性肌肉烟碱型乙酰胆碱受体的免疫原性。
Autoimmunity. 2012 May;45(3):245-52. doi: 10.3109/08916934.2011.622015. Epub 2011 Oct 21.
7
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.在实验性自身免疫性重症肌无力中,用硼替佐米抑制蛋白酶体可减少浆细胞和自身抗体。
J Immunol. 2011 Feb 15;186(4):2503-13. doi: 10.4049/jimmunol.1002539. Epub 2011 Jan 14.
8
Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.阻断白细胞介素-6 可抑制实验性自身免疫性重症肌无力。
J Autoimmun. 2011 Mar;36(2):135-41. doi: 10.1016/j.jaut.2010.12.001. Epub 2010 Dec 30.
9
Biochemical and electrophysiological properties of antibodies against pure acetylcholine receptor from vertebrate muscles and its subunits from Torpedo in relation to experimental myasthenia.
Neurochem Int. 1983;5(4):445-58. doi: 10.1016/0197-0186(83)90074-8.
10
Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.抗体效应机制在重症肌无力中的作用-神经肌肉接头的发病机制。
Autoimmunity. 2010 Aug;43(5-6):353-70. doi: 10.3109/08916930903555943.